Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
Sanofi's Sarclisa becomes the first cancer drug approved by the FDA for delivery via an on-body injector for multiple myeloma.
📍 Where it landed
The FDA approved Sanofi's subcutaneous Sarclisa Escena, a wearable on-body injector for multiple myeloma. This marked the first cancer drug delivered by an on-body injector.
Epilogue added 41d ago, after coverage quieted.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The US FDA has approved Sarclisa Escena (isatuximab-irfc), a subcutaneous formulation used to treat multiple myeloma. This marks the first time a cancer drug has been approved for delivery via a wearable, on-body injector.
Coverage from Reuters, Fierce Pharma, and Pharmaceutical Executive emphasizes the novelty of the delivery method. The Journal of Managed Care notes that this approval increases competition among anti-CD38 therapies.
Yahoo Finance further reports that this regulatory win coincides with the European Union opening an antitrust probe into Sanofi. Industry focus remains on the clinical implications of isatuximab-irfc's approval and the subsequent impact on the multiple myeloma treatment landscape.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 42d ago.
The reporting (10)
- Galina Bernstein: FDA Approves Subcutaneous Isatuximab for Multiple Myeloma Oncodaily · 45d ago
- FDA Approves Subcutaneous Isatuximab for Multiple Myeloma Oncodaily · 45d ago
- FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma Journal of Managed Care · 45d ago
- Sanofi (ENXTPA:SAN) Wins FDA Nod For Sarclisa Escena As EU Opens Antitrust Probe Yahoo Finance · 45d ago
- FDA Approves Isatuximab-Irfc For Subcutaneous Injection For Multiple Myeloma Indications On July 9 TradingView · 45d ago
- FDA Approves Subcutaneous Sarclisa Escena Pharmaceutical Executive · 45d ago
- The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma PharmTech.com · 45d ago
- Subcutaneous Sarclisa Escena Receives FDA Nod for Multiple Myeloma Medical Professionals Reference · 45d ago
- US FDA approves Sanofi's wearable injector form of blood cancer drug Reuters · 45d ago
- Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector Fierce Pharma · 45d ago broke it first
Quick answers
What is Sarclisa Escena used for?
It is used for the treatment of multiple myeloma.
What makes this FDA approval unique?
It is the first cancer drug approved for delivery through an on-body injector.
Which company developed the drug?
The drug was developed by Sanofi.
People, places & organizations
Topics
Related trends
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance to a new Alzheimer’s disease blood test developed by Roche and Eli Lilly.
US law to investigate foodborne illness outbreaks has been delayed for 15 years
A 15‑year freeze on a key food‑safety law is sparking congressional pressure as groups warn it hinders outbreak investigations.
Marketside soup sold at Walmart recalled over Listeria concerns: FDA
Marketside tomato bisque soup kits face a 29‑state recall over potential Listeria, hitting Walmart shoppers nationwide
Taylor Farms Voluntarily Recalls Fresh Jalapeños Over Salmonella Concerns
Taylor Farms recalls ready-to-eat foods and jalapeño products over salmonella concerns.
FDA approves 1st mRNA flu shot, from Moderna
The first mRNA-based influenza vaccine has received federal approval in the United States.
The FDA Issued a Recall on Thyroid Medication Nationwide
The FDA has issued a nationwide recall of levothyroxine sodium tablets due to the drug being described as subpotent.